Skip to main content
. Author manuscript; available in PMC: 2017 Apr 19.
Published in final edited form as: Adv Funct Mater. 2016 Feb 1;26(15):2512–2522. doi: 10.1002/adfm.201504879

Figure 6.

Figure 6

(a) Induction of OVA-specific humoral immune response 4 weeks after transdermal (t.d.) administration of HA-OVA (mean ± SD, n = 4). ***, P < 0.001, HA-OVA (500 μg of OVA) vs. HA-OVA with other OVA doses. (b) OVA-specific antibody titers measured at 2, 4 and 8 weeks after transdermal immunization with HA-OVA conjugate (500 μg of OVA) (mean ± SD, n = 4) and 4 days after OVA challenge test. **, P < 0.01; ***, P < 0.001, HA-OVA vs. OVA.